Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages

An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease

(2011) David A. Lomas et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease

(2011) David S. Millan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synergistic Effects of p38 Mitogen-Activated Protein Kinase Inhibition with a Corticosteroid in Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease

(2011) J. Armstrong et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages

(2009) J. Armstrong et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma

(2009) P. Bhavsar et al.   EUROPEAN RESPIRATORY JOURNAL

A Randomized, Placebo-Controlled Study of the Effects of the p38 MAPK Inhibitor SB-681323 on Blood Biomarkers of Inflammation in COPD Patients

(2009) Dave Singh et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

(2009) Leonardo M Fabbri et al.   LANCET

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

(2009) Peter MA Calverley et al.   LANCET

Associations of IL6 polymorphisms with lung function decline and COPD

(2009) J-Q He et al.   THORAX

Molecular Mechanisms of Corticosteroid Resistance

(2008) Ian M. Adcock et al.   CHEST

Tumour necrosis factor gene polymorphisms are associated with COPD

(2008) M. R. Gingo et al.   EUROPEAN RESPIRATORY JOURNAL

Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504)

(2008) L. M. Kent et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Increased activation of p38 MAPK in COPD

(2007) T. Renda et al.   EUROPEAN RESPIRATORY JOURNAL